Artivion (NYSE:AORT) CAO Amy Horton Sells 641 Shares

Artivion, Inc. (NYSE:AORT) CAO Amy Horton sold 641 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $38.02, for a total value of $24,370.82. Following the completion of the transaction, the chief accounting officer directly owned 132,514 shares in the company, valued at $5,038,182.28. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Amy Horton also recently made the following trade(s):

• On Tuesday, February 24th, Amy Horton sold 830 shares of Artivion stock. The shares were sold at an average price of $35.69, for a total value of $29,622.70.
• On Monday, February 23rd, Amy Horton sold 1,731 shares of Artivion stock. The stock was sold at an average price of $37.59, for a total value of $65,068.29.
• On Monday, December 8th, Amy Horton sold 4,572 shares of Artivion stock. The shares were sold at an average price of $44.42, for a total value of $203,088.24.

Artivion Trading Down 0.1%

AORT traded down $0.05 on Tuesday, reaching $38.50. 417,221 shares of the company’s stock were exchanged, compared to its average volume of 413,400. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $48.25. The company’s 50 day moving average is $41.77 and its 200-day moving average is $42.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The company has a market cap of $1.84 billion, a price-to-earnings ratio of 192.51 and a beta of 1.59.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The company had revenue of $118.30 million during the quarter, compared to the consensus estimate of $116.42 million. The firm’s quarterly revenue was up 19.2% on a year-over-year basis. Equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AORT. Vanguard Group Inc. increased its position in shares of Artivion by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Morgan Stanley increased its holdings in Artivion by 0.8% in the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock valued at $102,930,000 after buying an additional 18,248 shares during the last quarter. State Street Corp increased its holdings in Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after buying an additional 44,641 shares during the last quarter. Fred Alger Management LLC lifted its holdings in Artivion by 4.2% during the 4th quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after buying an additional 55,322 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Artivion by 211.9% in the 4th quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after acquiring an additional 748,119 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AORT. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Needham & Company LLC restated a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Oppenheimer reiterated an “outperform” rating and set a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group decreased their target price on shares of Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Finally, Weiss Ratings raised shares of Artivion from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, February 20th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Artivion has a consensus rating of “Moderate Buy” and an average target price of $48.97.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.